What's Happening?
A new experimental medication, enlicitide, has demonstrated significant cholesterol-lowering effects in a large clinical study. The phase three trial, published in The New England Journal of Medicine, revealed that the once-daily pill reduced low-density
lipoprotein (LDL) cholesterol levels by up to 60%. This reduction is the most substantial achieved by an oral drug since the development of statins. The study, led by Dr. Ann Marie Navar from UT Southwestern Medical Center, involved 2,909 participants who either had atherosclerosis or were at high risk due to related health conditions. Despite most participants already taking statins, their average LDL cholesterol levels remained above recommended targets. Enlicitide's ability to lower LDL cholesterol could offer a new method for millions in the U.S. to reduce their risk of heart attacks and strokes.
Why It's Important?
The development of enlicitide represents a significant advancement in cardiovascular disease prevention. With fewer than half of patients with established atherosclerotic cardiovascular disease reaching LDL cholesterol goals, this new oral therapy could dramatically improve prevention efforts on a population level. The drug's potential approval by the FDA could provide a more accessible and less invasive option compared to current injectable treatments, which are underutilized due to their administration method. This could lead to broader adoption and better management of cholesterol levels, ultimately reducing the incidence of heart attacks and strokes.
What's Next?
Researchers are conducting further clinical trials to determine if the reductions in LDL cholesterol achieved by enlicitide directly correlate with fewer heart attacks and strokes. If successful, these trials could pave the way for FDA approval and widespread use of the drug. The pharmaceutical company Merck & Co. Inc., which sponsored the study, is likely to continue its efforts to bring enlicitide to market, potentially transforming the landscape of cholesterol management.
